Literature DB >> 29509940

Multiplexed immunofluorescence reveals potential PD-1/PD-L1 pathway vulnerabilities in craniopharyngioma.

Shannon Coy1,2, Rumana Rashid1,2, Jia-Ren Lin2,3, Ziming Du1, Andrew M Donson4,5, Todd C Hankinson5,6, Nicholas K Foreman4,5, Peter E Manley2,7, Mark W Kieran2,7, David A Reardon2,8, Peter K Sorger2,3,9, Sandro Santagata1,2,3,9,10,11.   

Abstract

Background: Craniopharyngiomas are neoplasms of the sellar/parasellar region that are classified into adamantinomatous craniopharyngioma (ACP) and papillary craniopharyngioma (PCP) subtypes. Surgical resection of craniopharyngiomas is challenging, and recurrence is common, frequently leading to profound morbidity. BRAF V600E mutations render PCP susceptible to BRAF/MEK inhibitors, but effective targeted therapies are needed for ACP. We explored the feasibility of targeting the programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) immune checkpoint pathway in ACP and PCP.
Methods: We mapped and quantified PD-L1 and PD-1 expression in ACP and PCP resections using immunohistochemistry, immunofluorescence, and RNA in situ hybridization. We used tissue-based cyclic immunofluorescence to map the spatial distribution of immune cells and characterize cell cycle and signaling pathways in ACP tumor cells which intrinsically express PD-1.
Results: All ACP (15 ± 14% of cells, n = 23, average ± SD) and PCP (35 ± 22% of cells, n = 18) resections expressed PD-L1. In ACP, PD-L1 was predominantly expressed by tumor cells comprising the cyst lining. In PCP, PD-L1 was highly expressed by tumor cells surrounding the stromal fibrovascular cores. ACP also exhibited tumor cell-intrinsic PD-1 expression in whorled epithelial cells with nuclear-localized beta-catenin. These cells exhibited evidence of elevated mammalian target of rapamycin (mTOR) and mitogen-activated protein kinase (MAPK) signaling. Profiling of immune populations in ACP and PCP showed a modest density of CD8+ T cells. Conclusions: ACP exhibit PD-L1 expression in the tumor cyst lining and intrinsic PD-1 expression in cells proposed to comprise an oncogenic stem-like population. In PCP, proliferative tumor cells express PD-L1 in a continuous band at the stromal-epithelial interface. Targeting PD-L1 and/or PD-1 in both subtypes of craniopharyngioma might therefore be an effective therapeutic strategy.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29509940      PMCID: PMC6280314          DOI: 10.1093/neuonc/noy035

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  35 in total

1.  Craniopharyngiomas of adamantinomatous type harbor beta-catenin gene mutations.

Authors:  Shigeki Sekine; Tatsuhiro Shibata; Akiko Kokubu; Yukio Morishita; Masayuki Noguchi; Yukihiro Nakanishi; Michiie Sakamoto; Setsuo Hirohashi
Journal:  Am J Pathol       Date:  2002-12       Impact factor: 4.307

Review 2.  The pathogenesis of craniopharyngiomas.

Authors:  Vikram C Prabhu; Henry G Brown
Journal:  Childs Nerv Syst       Date:  2005-06-18       Impact factor: 1.475

Review 3.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

Authors:  David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison
Journal:  Acta Neuropathol       Date:  2016-05-09       Impact factor: 17.088

4.  Insights into the infiltrative behavior of adamantinomatous craniopharyngioma in a new xenotransplant mouse model.

Authors:  Christina Stache; Annett Hölsken; Sven-Martin Schlaffer; Andreas Hess; Markus Metzler; Benjamin Frey; Rudolf Fahlbusch; Jörg Flitsch; Michael Buchfelder; Rolf Buslei
Journal:  Brain Pathol       Date:  2014-05-19       Impact factor: 6.508

5.  Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.

Authors:  Esra A Akbay; Shohei Koyama; Julian Carretero; Abigail Altabef; Jeremy H Tchaicha; Camilla L Christensen; Oliver R Mikse; Andrew D Cherniack; Ellen M Beauchamp; Trevor J Pugh; Matthew D Wilkerson; Peter E Fecci; Mohit Butaney; Jacob B Reibel; Margaret Soucheray; Travis J Cohoon; Pasi A Janne; Matthew Meyerson; D Neil Hayes; Geoffrey I Shapiro; Takeshi Shimamura; Lynette M Sholl; Scott J Rodig; Gordon J Freeman; Peter S Hammerman; Glenn Dranoff; Kwok-Kin Wong
Journal:  Cancer Discov       Date:  2013-09-27       Impact factor: 39.397

Review 6.  CD20+ B cells: the other tumor-infiltrating lymphocytes.

Authors:  Brad H Nelson
Journal:  J Immunol       Date:  2010-11-01       Impact factor: 5.422

7.  Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.

Authors:  Naiyer A Rizvi; Matthew D Hellmann; Alexandra Snyder; Pia Kvistborg; Vladimir Makarov; Jonathan J Havel; William Lee; Jianda Yuan; Phillip Wong; Teresa S Ho; Martin L Miller; Natasha Rekhtman; Andre L Moreira; Fawzia Ibrahim; Cameron Bruggeman; Billel Gasmi; Roberta Zappasodi; Yuka Maeda; Chris Sander; Edward B Garon; Taha Merghoub; Jedd D Wolchok; Ton N Schumacher; Timothy A Chan
Journal:  Science       Date:  2015-03-12       Impact factor: 47.728

8.  Trends in treatment and outcomes of pediatric craniopharyngioma, 1975-2011.

Authors:  Michal Cohen; Ute Bartels; Helen Branson; Abhaya V Kulkarni; Jill Hamilton
Journal:  Neuro Oncol       Date:  2013-03-13       Impact factor: 12.300

9.  Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas.

Authors:  Priscilla K Brastianos; Amaro Taylor-Weiner; Peter E Manley; Robert T Jones; Dora Dias-Santagata; Aaron R Thorner; Michael S Lawrence; Fausto J Rodriguez; Lindsay A Bernardo; Laura Schubert; Ashwini Sunkavalli; Nick Shillingford; Monica L Calicchio; Hart G W Lidov; Hala Taha; Maria Martinez-Lage; Mariarita Santi; Phillip B Storm; John Y K Lee; James N Palmer; Nithin D Adappa; R Michael Scott; Ian F Dunn; Edward R Laws; Chip Stewart; Keith L Ligon; Mai P Hoang; Paul Van Hummelen; William C Hahn; David N Louis; Adam C Resnick; Mark W Kieran; Gad Getz; Sandro Santagata
Journal:  Nat Genet       Date:  2014-01-12       Impact factor: 38.330

10.  PD-1 blockade induces responses by inhibiting adaptive immune resistance.

Authors:  Paul C Tumeh; Christina L Harview; Jennifer H Yearley; I Peter Shintaku; Emma J M Taylor; Lidia Robert; Bartosz Chmielowski; Marko Spasic; Gina Henry; Voicu Ciobanu; Alisha N West; Manuel Carmona; Christine Kivork; Elizabeth Seja; Grace Cherry; Antonio J Gutierrez; Tristan R Grogan; Christine Mateus; Gorana Tomasic; John A Glaspy; Ryan O Emerson; Harlan Robins; Robert H Pierce; David A Elashoff; Caroline Robert; Antoni Ribas
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

View more
  20 in total

1.  Hyperspectral multiphoton microscopy for in vivo visualization of multiple, spectrally overlapped fluorescent labels.

Authors:  Amanda J Bares; Menansili A Mejooli; Mitchell A Pender; Scott A Leddon; Steven Tilley; Karen Lin; Jingyuan Dong; Minsoo Kim; Deborah J Fowell; Nozomi Nishimura; Chris B Schaffer
Journal:  Optica       Date:  2020-11-20       Impact factor: 11.104

2.  Treatment of Cystic Craniopharyngiomas: An Update.

Authors:  Federico Bianchi; Alberto Benato; Luca Massimi
Journal:  Adv Tech Stand Neurosurg       Date:  2022

Review 3.  Narrative online guides for the interpretation of digital-pathology images and tissue-atlas data.

Authors:  Rumana Rashid; Yu-An Chen; John Hoffer; Jeremy L Muhlich; Jia-Ren Lin; Robert Krueger; Hanspeter Pfister; Richard Mitchell; Sandro Santagata; Peter K Sorger
Journal:  Nat Biomed Eng       Date:  2021-11-08       Impact factor: 29.234

4.  Qualifying antibodies for image-based immune profiling and multiplexed tissue imaging.

Authors:  Ziming Du; Jia-Ren Lin; Rumana Rashid; Zoltan Maliga; Shu Wang; Jon C Aster; Benjamin Izar; Peter K Sorger; Sandro Santagata
Journal:  Nat Protoc       Date:  2019-09-18       Impact factor: 13.491

Review 5.  Medical Therapy for Craniopharyngiomas.

Authors:  Krystallenia I Alexandraki; Paraskevi Xekouki
Journal:  touchREV Endocrinol       Date:  2021-11-08

6.  Integrative Analysis of Biomarkers and Mechanisms in Adamantinomatous Craniopharyngioma.

Authors:  Da Lin; Wenyue Zhao; Jun Yang; Hao Wang; Hongbing Zhang
Journal:  Front Genet       Date:  2022-03-30       Impact factor: 4.599

7.  Highly multiplexed immunofluorescence images and single-cell data of immune markers in tonsil and lung cancer.

Authors:  Rumana Rashid; Giorgio Gaglia; Yu-An Chen; Jia-Ren Lin; Ziming Du; Zoltan Maliga; Denis Schapiro; Clarence Yapp; Jeremy Muhlich; Artem Sokolov; Peter Sorger; Sandro Santagata
Journal:  Sci Data       Date:  2019-12-17       Impact factor: 6.444

Review 8.  Spatial architecture of the immune microenvironment orchestrates tumor immunity and therapeutic response.

Authors:  Tong Fu; Lei-Jie Dai; Song-Yang Wu; Yi Xiao; Ding Ma; Yi-Zhou Jiang; Zhi-Ming Shao
Journal:  J Hematol Oncol       Date:  2021-06-25       Impact factor: 17.388

Review 9.  Emerging role of mTOR in tumor immune contexture: Impact on chemokine-related immune cells migration.

Authors:  Jing Jin; Qijie Zhao
Journal:  Theranostics       Date:  2020-05-15       Impact factor: 11.556

10.  Genetic and immune profiling for potential therapeutic targets in adult human craniopharyngioma.

Authors:  Cynthia Kassab; Daniel Zamler; Carlos Kamiya-Matsuoka; Zoran Gatalica; Joanne Xiu; David Spetzler; Amy B Heimberger
Journal:  Clin Oncol Res       Date:  2019-06-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.